UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000047266 |
|---|---|
| Receipt number | R000053908 |
| Scientific Title | Comparison of treatment satisfaction after switching from Semaglutide to Dulaglutide in patients with type 2 diabetes:a pilot study |
| Date of disclosure of the study information | 2022/03/23 |
| Last modified on | 2023/02/24 11:58:13 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Comparison of treatment satisfaction after switching from Semaglutide to Dulaglutide in patients with type 2 diabetes:a pilot study
Acronym
Comparison of treatment satisfaction after switching from Semaglutide to Dulaglutide in patients with type 2 diabetes:a pilot study
Scientific Title
Comparison of treatment satisfaction after switching from Semaglutide to Dulaglutide in patients with type 2 diabetes:a pilot study
Scientific Title:Acronym
Comparison of treatment satisfaction after switching from Semaglutide to Dulaglutide in patients with type 2 diabetes:a pilot study
Region
| Japan |
Condition
Condition
Type 2 diabetes
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
In Japanese patients with type 2 diabetes, the weekly preparation of semaglutide 0.5 mg is changed to duraglutide 0.75 mg, which is administered for 6 months, and the patient's treatment satisfaction is compared.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Explanatory
Developmental phase
Not applicable
Assessment
Primary outcomes
Difference from baseline in DTSQ 6 months after test start
Key secondary outcomes
Body weight, blood pressure, pulse rate, liver function (AST, ALT, gamma GTP), renal function (BUN, Cr, eGFR), uric acid, urinary microalbumin, HbA1c, fasting blood glucose, C-peptide level, diabetic retinopathy, etc. Complications Symptoms, adverse events (nausea, vomiting, etc.)
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
NO
Dynamic allocation
NO
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
No need to know
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
dulaglutide
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
(1)Patients who are over 20 years old at registration (regardless of gender)
(2)Patients diagnosed with type 2 diabetes
(3)Patients using liraglutide (0.6mg/0.9mg)
(4)Patients who have not been treated with a new diabetes drug for more than 3 months
(5)Patients who give their consent to participate in this study
Key exclusion criteria
(1) Patients with severe liver damage (up to 3 times normal upper limit of AST and ALT within 28 days before registration)
(2) Patients with severe congestive heart failure and acute heart failure
(3) Patients taking steroids
(4) Patients with a history of diabetic ketoacidosis or diabetic coma during the past 6 months
(5) Cancer patients currently undergoing treatment
(6) Patients with severe infections, before and after surgery, with severe trauma
(7) Patients who are contraindicated or allergic to the test drug
(8) Pregnant, possibly pregnant, or wishing to become pregnant during the treatment period and lactating patients
(9) Patients who participated in clinical trials or clinical trials of drugs or medical devices at the same time as this study or within 30 days before enrollment in this study
(10) Other patients who are judged to be unsuitable as subjects by the judgment of a doctor
Target sample size
15
Research contact person
Name of lead principal investigator
| 1st name | Terauchi |
| Middle name | |
| Last name | Yasuo |
Organization
Yokohama City University Hospital
Division name
Department of Endocrinology & Metabolism
Zip code
236-0004
Address
3-9 Fukuura, Kanazawa-ku, Yokohama
TEL
045-787-2800
terauchi@yokohama-cu.ac.jp
Public contact
Name of contact person
| 1st name | Iijima |
| Middle name | |
| Last name | Takahiro |
Organization
Yokosuka Kyosai Hospital
Division name
Department of Endocrinology & Metabolism
Zip code
238-8558
Address
1-16 Yonegahamadori, Yokosuka, Kanagawa
TEL
046-822-2710
Homepage URL
takahiro-iijima@umin.ac.jp
Sponsor or person
Institute
Yokosuka Kyosai Hospital
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Yokohama City University Hospital
Address
3-9 Fukuura, Kanazawa-ku, Yokohama
Tel
045-787-2800
onodera@yokohama-cu.ac.jp
Secondary IDs
Secondary IDs
YES
Study ID_1
21-87
Org. issuing International ID_1
Yokosuka Kyosai Hospital
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
横須賀共済病院（神奈川県）
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 03 | Month | 23 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2022 | Year | 03 | Month | 18 | Day |
Date of IRB
| 2022 | Year | 03 | Month | 18 | Day |
Anticipated trial start date
| 2022 | Year | 03 | Month | 24 | Day |
Last follow-up date
| 2023 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
| 2023 | Year | 04 | Month | 30 | Day |
Date trial data considered complete
| 2023 | Year | 04 | Month | 30 | Day |
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2022 | Year | 03 | Month | 23 | Day |
Last modified on
| 2023 | Year | 02 | Month | 24 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053908
